ASCIA Plans for FPIES, FPIAP/FPE and EoE
ASCIA has been providing Action, Management and Treatment plans since 2003, which are available open access on the ASCIA website. In addition to ASCIA Action Plans for Anaphylaxis (severe allergic reactions) ASCIA has Action and/or Management Plans for the following adverse reactions to foods:
- Food Protein Induced Allergic Proctocolitis (FPIAP) and Food Protein Enterocolitis (FPE)
- Food Protein Induced Enterocolitis Syndrome (FPIES)
- Eosinophilic Oesophagitis (EoE)
Food Protein Induced Allergic Proctocolitis (FPIAP) and Food Protein Enterocolitis (FPE)
ASCIA Management Plan for Delayed Reactions to Food (FPIAP, FPE)
- FPIAP is a delayed non-IgE mediated food allergy, associated with blood and mucus in stool, and diarrhoea in an otherwise thriving infant.
- FPE is a delayed non-IgE mediated food allergy associated with diarrhoea, abdominal pain, vomiting, and sometimes faltering growth.
- Unlike IgE mediated food allergy, FPIAP and FPE do not cause anaphylaxis (severe allergic reactions), that can be life threatening.
Food Protein Induced Enterocolitis Syndrome (FPIES)
- FPIES is a delayed, non-IgE mediated gastrointestinal system (gut) food allergy.
- FPIES causes allergic reactions to food/s that involves the gut and usually starts in the first two years of life.
- Unlike IgE mediated food allergy, FPIES does not cause anaphylaxis (severe allergic reactions), that can be life threatening.
Eosinophilic Oesophagitis (EoE)
- EoE occurs when white blood cells called eosinophils build up in the lining of the oesophagus, which is the muscular tube that connects the mouth to the stomach. This can be due to an allergic reaction to food or other causes in the environment.
- Most cases of EoE are seen in people with other allergies such as allergic rhinitis (hay fever) and asthma.
- The number of adults and children with EoE appears to be increasing but it is not known why.
More information about these conditions is available on the ASCIA website.
This news item was issued on 11 December 2024 by Jill Smith, CEO of ASCIA, the peak professional body for clinical immunology and allergy in Australia and New Zealand.